Aims/hypothesis Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of cholesterol homeostasis. PCSK9 inhibitors are being actively developed to lower LDL-cholesterol levels. However, there are conflicting data regarding the consequences of Pcsk9 deficiency on glucose homeostasis in mouse models. Here, we analysed in humans the association between the PCSK9 p.R46L loss-of-function (LOF) variant and (1) glucose homeostasis variables; (2) type 2 diabetes status; and (3) the risk of 9 year incident type 2 diabetes in a prospective study. Methods PCSK9 p.R46L was genotyped in 4630 French participants from the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study and in 1342 French participants with type 2 diabetes. The association between p.R46L and metabolic traits or type 2 diabetes risk was assessed through linear or logistic regression models adjusted for age, sex and BMI. The association between p.R46L and incident type 2 diabetes was assessed using a Cox regression model adjusted for sex, age and BMI at baseline. Results Significant associations (p<10 −6 ) were found between p.R46L and lower total cholesterol (−0.394 mmol/l), LDL-cholesterol (−0.393 mmol/l) and apolipoprotein B concentrations (−0.099 g/l). However, no significant association was observed between p.R46L and markers of glucose homeostasis (including fasting glucose, fasting insulin, HbA 1c , HOMA-B, HOMA-IR) or type 2 diabetes risk. Furthermore, no significant association between p.R46L variant and risk of incident type 2 diabetes was observed in DESIR.
Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the ninth member of the proprotein convertase family and is a key regulator of cholesterol homeostasis. PCSK9 is secreted by the liver and acts as an endogenous inhibitor of the LDL receptor (LDLR). PCSK9 loss-of-function (LOF) mutations contribute to low levels of plasma LDL-cholesterol and protection against cardiovascular diseases [1, 2] . For instance, the PCSK9 LOF low-frequent variant p.R46L (rs11591147; minor allele frequency in the HapMap-CEU (Centre d'Etude du Polymorphisme [Utah residents with northern and western European ancestry] population: 2.8%) has been shown to increase the number of cell surface LDLRs in hepatocytes in vitro [3] , leading to a mean reduction in LDL-cholesterol of 9% to 16% in p.R46L carriers. Recently, several Phase 3 trials have been conducted with human monoclonal antibodies directed against PCSK9 in patients with cardiovascular diseases, or familial or primary hypercholesterolaemia. PCSK9 inhibition has led to a drastic and consistent reduction in baseline LDL-cholesterol levels of up to~60%, independent of background lipid-lowering therapy [4] .
As well as being expressed mainly in the liver, PCSK9 is also expressed in mouse and human pancreatic islets and is able to downregulate the LDLR in human isolated islets [5] . Since it has been suspected that LDLR mediated lipotoxicity can alter beta cell function [6] , a potential safety issue with the use of PCSK9 inhibitors is the increased risk of type 2 diabetes. However, results obtained from Pcsk9-deficient mice are discordant. One study found no deleterious effect of Pcsk9 deficiency on glucose homeostasis [5] , while another demonstrated that Pcsk9-deficient mice are glucose intolerant with reduced insulin secretion [7] .
The aim of the present study was to assess the associations between the PCSK9 p.R46L variant and (1) changes in several glucose and lipid homeostasis variables in non-diabetic French participants; (2) type 2 diabetes in a French case-control study; (3) the incidence of type 2 diabetes over a 9 year follow-up period.
Methods
Study populations Genotyping of p.R46L was performed in two European-French populations: the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) and Corbeil studies.
The DESIR cohort is a 9 year longitudinal study in a French general population. We analysed 4630 DESIR participants successfully genotyped for p.R46L, of whom 4319 were nondiabetic during the follow-up period, 2207 had normal glucose homeostasis (and were used as controls in the case-control study), 127 presented with type 2 diabetes at baseline (and were used as cases in the case-control study) and 184 developed type 2 diabetes during the 9 year follow-up.
The Corbeil study included 1342 unrelated French type 2 diabetes patients successfully genotyped for p.R46L who were recruited by the Endocrinology-Diabetology Department of the Corbeil-Essonnes Hospital (Corbeil-Essonnes, France).
Glycaemic status was defined according to 1997 ADA criteria; normal glucose homeostasis was defined as a fasting plasma glucose (FPG) level <6.1 mmol/l without glucoselowering treatment, and type 2 diabetes was defined as FPG ≥7.0 mmol/l or treatment with glucose-lowering agents. Nondiabetic participants had FPG <7 mmol/l and were not treated with glucose-lowering agents.
The study protocol was approved by the local ethics committees and all participants provided written informed consent.
Genotyping of p.R46L variant Genotyping of the p.R46L variant (rs11591147) was performed using Metabochip DNA arrays (Illumina, San Diego, CA, USA), as previously described [8] . The individual call rate for the DESIR and Corbeil participants was >98% for the p.R46L variant and no departures from the Hardy-Weinberg equilibrium were observed in either study (p>0.05). Cluster plots are shown in electronic supplementary material (ESM) Fig. 1 .
Index calculation HOMA-B and HOMA-IR were calculated as previously described [9] .
Statistical analyses The associations between p.R46L and quantitative traits was assessed in 4319 non-diabetic participants from DESIR through linear regression models adjusted for age, sex and BMI (except for the analysis of BMI, which was adjusted for age and sex only).
The case-control analysis included type 2 diabetes participants from DESIR (at baseline) and from Corbeil, and normal glucose controls from DESIR (during the follow-up period). The association between p.R46L and type 2 diabetes was assessed using a logistic regression model adjusted for age, sex and BMI.
The association between p.R46L and incident type 2 diabetes was assessed in DESIR using a Cox regression model adjusted for sex, age and BMI at baseline, and the timescale used was age.
All the analyses were performed under an additive model. Given the size of our studies, we would have been able to detect a significant OR of 1.55 (type 2 diabetes case-control study) and a significant HR of 4.40 (incident type 2 diabetes study), with a power of 80% (ESM Fig. 2 ).
Except for statistical power analyses, we performed statistical analyses using SPSS (version 14.0), IBM, Armonk, NY, USA.
Results
In the 4,319 non-diabetic participants from the DESIR study, we assessed the association of PCSK9 p.R46L with BMI, glucose homeostasis related traits ( 
Discussion
The major finding of this study is that the PCSK9 p.R46L LOF variant was not associated with impaired glucose homeostasis in humans. Notably, we showed that p.R46L carriers did not have an increased incidence of type 2 diabetes during a 9 year follow-up or type 2 diabetes risk in a case-control study.
Although positive correlations were observed between plasma PCSK9 and both FPG and HOMA-IR in the Dallas Heart Study [12] , we did not find any associations between p.R46L and either FPG, HbA 1c , or markers of insulin resistance (HOMA-IR) or insulin secretion (HOMA-B) . However, a non-clinically relevant tendency for a positive association between p.R46L and FPG was observed in MAGIC. As expected [1, 2], p.R46L remained associated with markers of LDL metabolism with reduced total cholesterol, LDLcholesterol and APOB concentrations in people carrying the p.R46L allele. The use of statins is associated with an increased risk of type 2 diabetes and could be a potential confounding factor [13] . However, adding lipid-lowering medication status into the model did not modify the results.
The present results are in line with our previous results obtained in PCSK9-deficient mice, in which there was no alteration of glucose homeostasis, as assessed by both glucose and insulin tolerance tests [5] . While PCSK9 deficiency is associated with an increased expression of LDLR in pancreatic islets, there is no increase in intracellular cholesterol content in PCSK9-deficient islets, even under lipotoxic conditions when incubating isolated islets with high concentrations of LDL [5] . This absence of intracellular cholesterol accumulation might be due to reduced circulating LDL levels in PCSK9-deficient mice and/or to an increase in cholesterol efflux from beta cell. ALAT, alanine aminotransferase; AST, aspartate aminotransferase; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TC, total cholesterol; TG, triacylglycerol
Our study has several limitations that should be highlighted. First, we only focussed on the effect of the most frequent PCSK9 LOF variant, i.e. p.R46L, and we cannot exclude the possibility that other rare PCSK9 LOF mutations with stronger functional effects may alter glucose homeostasis. Second, the intensity of PCSK9 inhibition observed in heterozygous carriers of the p.R46L variant is inferior to those obtained with PCSK9 monoclonal antibodies. Indeed, the decrease of LDL-cholesterol is 10% in p.R46L carriers compared with~60% with alirocumab or evolocumab in Phase 2 trials [4] . However, such a small decrease in LDLcholesterol was consistently associated with a highly significant reduction of cardiovascular events in individuals carrying the p.R46L allele [1, 2], certainly because it was maintained throughout their lives.
In conclusion, a genetic PCSK9 deficiency is not associated with an increased risk of type 2 diabetes. These data are reassuring regarding the safety of PCSK9 inhibitors. Precise glucose phenotyping of individuals treated with PCSK9 monoclonal antibodies in ongoing Phase 3 trials will give some additional insights into the relationship between PCSK9 and glucose homeostasis.
